Dear Colleagues,

The scenario of viral hepatitis, mainly referring to hepatitis B and C, has changed rapidly in recent years due to prevention interventions and increasingly effective antiviral therapies. Considering these advances, the WHO set the goal of eliminating viral hepatitis as a major public health threat by 2030. This goal, however, still represents an open challenge because of important issues. These include the high number of undiagnosed people, inadequate prophylaxis and poor access to therapy for disadvantaged populations, and the complexity of assessing progress towards established goals.

In addition, the SARS-CoV-2 pandemic has hampered the management of people with viral hepatitis. In fact, it was documented that it led to a reduction in testing and initiation of treatments. Several efforts to counter this situation and stay in line with WHO goals have been conducted around the world, such as hepatitis C screening programs leveraging COVID-19 related services.

This Special Issue aims to collect articles on various aspects of viral hepatitis, including epidemiology, prevention, infection, screening strategies, and recent advances in antiviral therapies. In addition, articles analyzing the impact of the SARS-CoV-2 pandemic on patients with viral hepatitis and proposing how to maintain an adequate rate of identification and treatment despite the reorganization of health services will be considered.

Prof. Dr. Marcello Persico
Dr. Pietro Torre
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatitis A
• hepatitis B
• hepatitis C
• hepatitis D
• hepatitis E
• hepatitis C screening
• viral hepatitis elimination